版本:
中国

BRIEF-Catabasis Pharma & Sarepta Therapeutics to collaborate in Duchenne muscular dystrophy

Sept 29 Catabasis Pharmaceuticals Inc :

* Collaboration to study exon skipping treatment by Sarepta with co's oral NF-KB inhibition treatment in mouse model of DMD

* Catabasis Pharmaceuticals and Sarepta Therapeutics announce a joint research collaboration in Duchenne muscular dystrophy

* Collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy Source text for Eikon: Further company coverage: ;))

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐